New pill tested in fight against Tough-to-Treat cancers
NCT ID NCT04390737
Summary
This early-stage study is testing a new oral medication called HH2853 in adults with advanced cancers that have come back or stopped responding to standard treatments. The main goals are to find a safe and tolerable dose and to see if the drug shows any early signs of helping to control cancers like lymphoma and sarcoma. The study will enroll about 254 participants and is currently recruiting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Drum Tower Hospital, Medical School of Nanjing University
RECRUITINGNanjing, Jiangsu, China
Contact Email: •••••@•••••
-
Affiliated Tumor Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, China
Contact Email: •••••@•••••
Contact
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Email: •••••@•••••
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
-
Beijing Jishuitan Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, China
Contact Email: •••••@•••••
Contact
-
Liaoning Cancer Hospital&Institute
RECRUITINGShenyang, Liaoning, China
Contact Email: •••••@•••••
-
Linyi Tumor Hospital
RECRUITINGLinyi, Shandong, China
Contact Email: •••••@•••••
-
Mayo Clinic
COMPLETEDPhoenix, Arizona, 85054, United States
-
Mayo Clinic
COMPLETEDJacksonville, Florida, 32224, United States
-
Mayo Clinic
COMPLETEDRochester, Minnesota, 55905, United States
-
NEXT Oncology
COMPLETEDSan Antonio, Texas, 78240, United States
-
Shanghai Sixth People's Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
-
Shanxi Cancer Hospital
RECRUITINGTaiyuan, Shanxi, China
Contact Email: •••••@•••••
-
Shengjing Hospital Of China Medical University
RECRUITINGShenyang, Liaoning, China
Contact Email: •••••@•••••
-
Sun Yat-Sen University Cancer Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact
Contact Email: •••••@•••••
-
Sun Yat-Sen University Cancer Hospital
RECRUITINGGuangzhou, China
Contact Email: •••••@•••••
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, China
Contact Email: •••••@•••••
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact
Contact Email: •••••@•••••
Contact
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact
Contact Email: •••••@•••••
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact Email: •••••@•••••
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact
Contact Email: •••••@•••••
-
Zhongshan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.